Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 8, 2010, Pages 1495-1499

  Chen, Chih Ken ^a,b,c   Huang, Yu Shu ^a,b   Ree, Shao Chun ^a,b   Hsiao, Cheng Cheng ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Antipsychotics; Aripiprazole; Prolactin; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; PROLACTIN; RISPERIDONE; SULPIRIDE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; ADULT; AKATHISIA; ANXIETY; ARIZONA SEXUAL EXPERIENCE SCALE; ARTICLE; BARNES AKATHISIA SCALE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; RATING SCALE; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SIMPSON ANGUS SCALE; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZAMIDES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PIPERAZINES; PROLACTIN; PROSPECTIVE STUDIES; QUINOLONES; RISPERIDONE; YOUNG ADULT;

EID: 78649506539     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2010.08.012     Document Type: Article

References (28)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washinton, DC.
2. Barnes T.R. The Barnes Akathisia Rating Scale-revisited. J Psychopharmacol 2003, 17:365-370.
3. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002, 302:381-389.
4. Byerly M.J., Marcus R.N., Tran Q.V., Eudicone J.M., Whitehead R., Baker R.A. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res 2009, 107:218-222.
5. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003, 166:391-399.
6. Grunder G., Wetzel H., Schlosser R., Anghelescu I., Hillert A., Lange K., et al. Neuroendocrine response to antipsychotics: effects of drug type and gender. Biol Psychiatry 1999, 45:89-97.
7. Guy W. ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338 1976, 534-537. National Institute of Mental Health, Rockville, MD.
8. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64:2291-2314.
9. Hoffer Z.S., Roth R.L., Mathews M. Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia. Psychosomatics 2009, 50:317-324.
10. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., et al. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009, 70:1348-1357.
11. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 2002, 302:1129-1134.
12. Kay S.R., Opler L.A., Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual 1986, Multi-Health System, New York.
13. Keck P.E., Marcus R., Tourkodimitris S., Ali M., Liebeskind A., Saha A., et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003, 160:1651-1658.
14. Lee B.H., Kim Y.K., Park S.H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:714-717.
15. Lin S.K., Chen C.K. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry 2006, 67:1307.
16. Lu M.L., Shen W.W., Chen C.H. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1978-1981.
17. Maguire G.A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002, 63(Suppl 4):56-62.
18. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003, 61:123-136.
19. McGahuey C.A., Gelenberg A.J., Laukes C.A., Moreno F.A., Delgado P.L., McKnight K.M., et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000, 26:25-40.
20. Paulzen M., Grunder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 2007, 10:149-151.
21. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl 20):22-33.
22. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007, 164:1404-1410.
23. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19.
24. Turrone P., Kapur S., Seeman M.V., Flint A.J. Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 2002, 159:133-135.
25. Wahl R., Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 2005, 162:1542-1543.
26. Wetzel H., Wiesner J., Hiemke C., Benkert O. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers. J Psychiatr Res 1994, 28:461-473.
27. Wieck A., Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003, 182:199-204.
28. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2000, 284:3043-3045.